Terapet announces international collaboration for Heavy Ion Therapy QA
Terapet SA are proud to announce an international collaboration to develop a world-first device for patient-specific QA in heavy ion therapy (HIT). Terapet will be joined in the collaboration by Korean partners Yonsei Cancer Center and Oncosoft Inc, who together bring vital medical expertise and software innovations to be united with Terapet’s novel nuclear imaging technology. The project, worth almost CHF 3’000’000 over the next 3 years, is funded by a bilateral grant from the Korea Institute for Advancement of Technology (KIAT) and the Swiss Innovation Agency (Innosuisse).
The collaboration agreement was signed during the FARO-KOSRO 2023 congress in Seoul, Korea. Terapet’s CEO, Christina Vallgren, welcomed the collaboration, saying “Together, we’re not just merging resources; we’re uniting our strengths across two countries and continents, making a real impact for the future of heavy ion therapy.”
A full press release is attached.
Local news:
Koran news:
Linkedin post here.
Prof. Han (Professor of Yonsei Cancer Center), Dr. Chun (CSO of Oncosoft), Prof. Dong Wook Kim (Clinical Professor, Yonsei Cancer Center), Laura Acosta (Swiss Embassy Representative), Prof. Ik Jae Lee (Director of Heavy Ion Therapy, Yonsei Cancer Center), Dr. Christina Vallgren (CEO of Terapet), Herve Duffour (Sales and Marketing director of Terapet), Prof. Jin Sung Kim (Chief Medical Physicist of Yonsei Cancer Center & CEO of Oncosoft).
